Articles
CAR-T Cell Therapy Accessibility: A Targeted Review of Access Challenges and Opportunities in APAC Region
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Krishna A1, Verma A1, Pruthi J1, Prasanna R1, Rai MK2 | 1EVERSANA, Mumbai, MH, India, 2EVERSANA, Singapore, Singapore
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in Canada
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Udeze C1, Gargano M1, Kaindl L2, Kane S2, Zhou A2, Jain S1, Lopez A | 1 1Vertex Pharmaceuticals Incorporated, Boston, MA, USA, 2Eversana, Burlington, ON, Canada
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases
Budget Impact Analyses of Hemoglobin a1C and Lipid Panel Point-of-Care Testing With Afinion™ 2 in Italy and Canada
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Garcia D1, Ruffolo A2, Walczyk Mooradally A3, Zhou A1, Lazaridis E4, Laurelli B5 | 1EVERSANA, Burlington, ON, Canada, 2Abbott Rapid Diagnostics, Köln, NW, Germany, 3EVERSANA, Waterdown, ON, Canada, 4Abbott Rapid Diagnostics, Ottawa, ON, Canada, 5Abbott Rapid Diagnostics, Sesto San Giovanni, MI, Italy
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
Treatment Patterns and Economic Burden of Guillain-Barré Syndrome: A Systematic Review
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Jangid S1, Pruthi J1, Prasanna R2, Rai MK2 | 1EVERSANA, Mumbai, MH, India, 2EVERSANA, Singapore, Singapore
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases
Evaluating the Clinical and Socioeconomic Impact of Improved CKD Diagnosis and Adherence to Guideline-Directed Medical Therapy in Australia, Brazil, and China: An Impact CKD Analysis
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Rao N1, Wyman CS1, Chen J2, Priest S3, Brown S3, Moura AF4, Zhao MH5, Chadban S6 | 1AstraZeneca, BioPharmaceuticals Medical, Cambridge, Cambridgeshire, UK, 2AstraZeneca, Gaithersburg, MD, USA, 3EVERSANA, Burlington, ON, Canada, 4Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil, 5Peking University Institute of Nephrology, Beijing, Hebei, China, 6Royal Prince Alfred Hospital, Sydney, Australia
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Urinary/Kidney Disorders
Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Transfusion-Dependent Beta-Thalassemia in Canada
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Udeze C1, Gargano M1, Kaindl L2, Kane S2, Zhou A2, Jain S1, Lopez A1 | 1Vertex Pharmaceuticals Incorporated, Boston, MA, USA, 2Eversana, Burlington, ON, Canada
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases
Systematic Literature Review of Cost-Effectiveness Evaluations of Freestyle Libre Continuous Glucose Monitoring Systems
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- De Pouvourville G1, Timmons J2, Levrat Guillen F2, Zara A3, Poon Y2 | 1ESSEC, Paris, Ile de France, France, 2Abbott Diabetes Care, Alameda, CA, USA, 3Eversana, Burlington, ON, Canada
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Diabetes/Endocrine/Metabolic Disorders
Systematic Literature Review (SLR) of Randomized Controlled Trials (RCTs) of Treatments for First-Line (1L) Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (GC/GEJ) in Adult Patients
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Smyth E1, Kangappaden T2, Portuhay S2, Debnath A2, Craigie S2, Coaquira Castro J3, Priedane E4, Zhan L3 | 1Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK, 2EVERSANA, Burlington, ON, Canada, 3BeiGene USA, Inc., Emeryville, CA, USA, 4BeiGene UK, Ltd., London, LON, UK
- Publication Date:
- Literature Review & Synthesis
- Condition:
- Oncology
Patient-Centric Approaches in Rare Disorder Research: An In-Depth Systematic Review
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Verma A1, Chinchapattanam D1, Barathe P1, Krishna A1, Pruthi J1, Rai MK2, Prasanna R1 | 1EVERSANA, Mumbai, MH, India, 2EVERSANA, Singapore, Singapore
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases
NICE vs SMC: Reimbursement Differences for Non-Oncology Orphan Drugs
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Dey R, EVERSANA, Pune, India
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases